Utilizing the adjuvant properties of CD1d-dependent NK T cells in T cell-mediated immunotherapy.
Activation of invariant CD1d-dependent NK T cells (iNKT cells) in vivo through administration of the glycolipid ligand alpha-galactosylceramide (alpha-GalCer) or the sphingosine-truncated alpha-GalCer analog OCH leads to CD40 signaling as well as the release of soluble molecules including type 1 and...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2004
|
| _version_ | 1797061668786667520 |
|---|---|
| author | Silk, J Hermans, I Gileadi, U Chong, T Shepherd, D Salio, M Mathew, B Schmidt, R Lunt, S Williams, K Stratford, I Harris, A Cerundolo, V |
| author_facet | Silk, J Hermans, I Gileadi, U Chong, T Shepherd, D Salio, M Mathew, B Schmidt, R Lunt, S Williams, K Stratford, I Harris, A Cerundolo, V |
| author_sort | Silk, J |
| collection | OXFORD |
| description | Activation of invariant CD1d-dependent NK T cells (iNKT cells) in vivo through administration of the glycolipid ligand alpha-galactosylceramide (alpha-GalCer) or the sphingosine-truncated alpha-GalCer analog OCH leads to CD40 signaling as well as the release of soluble molecules including type 1 and gamma interferons that contribute to DC maturation. This process enhances T cell immunity to antigens presented by the DC. The adjuvant activity is further amplified if APCs are stimulated through Toll-like receptor 4, suggesting that iNKT cell signals can amplify maturation induced by microbial stimuli. The adjuvant activity of alpha-GalCer enhances both priming and boosting of CD8(+) T cells to coadministered peptide or protein antigens, including a peptide encoding the clinically relevant, HLA-A2-restricted epitope of the human tumor antigen NY-ESO-1. Importantly, alpha-GalCer was used to induce CD8(+) T cells to antigens delivered orally, despite the fact that this route of administration is normally associated with blunted responses. Only T cell responses induced in the presence of iNKT cell stimulation, whether by the i.v. or oral route, were capable of eradicating established tumors. Together these data highlight the therapeutic potential of iNKT cell ligands in vaccination strategies, particularly "heterologous prime-boost" strategies against tumors, and provide evidence that iNKT cell stimulation may be exploited in the development of oral vaccines. |
| first_indexed | 2024-03-06T20:34:32Z |
| format | Journal article |
| id | oxford-uuid:322c8689-e518-4bf2-93c5-c8869774c223 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T20:34:32Z |
| publishDate | 2004 |
| record_format | dspace |
| spelling | oxford-uuid:322c8689-e518-4bf2-93c5-c8869774c2232022-03-26T13:12:26ZUtilizing the adjuvant properties of CD1d-dependent NK T cells in T cell-mediated immunotherapy.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:322c8689-e518-4bf2-93c5-c8869774c223EnglishSymplectic Elements at Oxford2004Silk, JHermans, IGileadi, UChong, TShepherd, DSalio, MMathew, BSchmidt, RLunt, SWilliams, KStratford, IHarris, ACerundolo, VActivation of invariant CD1d-dependent NK T cells (iNKT cells) in vivo through administration of the glycolipid ligand alpha-galactosylceramide (alpha-GalCer) or the sphingosine-truncated alpha-GalCer analog OCH leads to CD40 signaling as well as the release of soluble molecules including type 1 and gamma interferons that contribute to DC maturation. This process enhances T cell immunity to antigens presented by the DC. The adjuvant activity is further amplified if APCs are stimulated through Toll-like receptor 4, suggesting that iNKT cell signals can amplify maturation induced by microbial stimuli. The adjuvant activity of alpha-GalCer enhances both priming and boosting of CD8(+) T cells to coadministered peptide or protein antigens, including a peptide encoding the clinically relevant, HLA-A2-restricted epitope of the human tumor antigen NY-ESO-1. Importantly, alpha-GalCer was used to induce CD8(+) T cells to antigens delivered orally, despite the fact that this route of administration is normally associated with blunted responses. Only T cell responses induced in the presence of iNKT cell stimulation, whether by the i.v. or oral route, were capable of eradicating established tumors. Together these data highlight the therapeutic potential of iNKT cell ligands in vaccination strategies, particularly "heterologous prime-boost" strategies against tumors, and provide evidence that iNKT cell stimulation may be exploited in the development of oral vaccines. |
| spellingShingle | Silk, J Hermans, I Gileadi, U Chong, T Shepherd, D Salio, M Mathew, B Schmidt, R Lunt, S Williams, K Stratford, I Harris, A Cerundolo, V Utilizing the adjuvant properties of CD1d-dependent NK T cells in T cell-mediated immunotherapy. |
| title | Utilizing the adjuvant properties of CD1d-dependent NK T cells in T cell-mediated immunotherapy. |
| title_full | Utilizing the adjuvant properties of CD1d-dependent NK T cells in T cell-mediated immunotherapy. |
| title_fullStr | Utilizing the adjuvant properties of CD1d-dependent NK T cells in T cell-mediated immunotherapy. |
| title_full_unstemmed | Utilizing the adjuvant properties of CD1d-dependent NK T cells in T cell-mediated immunotherapy. |
| title_short | Utilizing the adjuvant properties of CD1d-dependent NK T cells in T cell-mediated immunotherapy. |
| title_sort | utilizing the adjuvant properties of cd1d dependent nk t cells in t cell mediated immunotherapy |
| work_keys_str_mv | AT silkj utilizingtheadjuvantpropertiesofcd1ddependentnktcellsintcellmediatedimmunotherapy AT hermansi utilizingtheadjuvantpropertiesofcd1ddependentnktcellsintcellmediatedimmunotherapy AT gileadiu utilizingtheadjuvantpropertiesofcd1ddependentnktcellsintcellmediatedimmunotherapy AT chongt utilizingtheadjuvantpropertiesofcd1ddependentnktcellsintcellmediatedimmunotherapy AT shepherdd utilizingtheadjuvantpropertiesofcd1ddependentnktcellsintcellmediatedimmunotherapy AT saliom utilizingtheadjuvantpropertiesofcd1ddependentnktcellsintcellmediatedimmunotherapy AT mathewb utilizingtheadjuvantpropertiesofcd1ddependentnktcellsintcellmediatedimmunotherapy AT schmidtr utilizingtheadjuvantpropertiesofcd1ddependentnktcellsintcellmediatedimmunotherapy AT lunts utilizingtheadjuvantpropertiesofcd1ddependentnktcellsintcellmediatedimmunotherapy AT williamsk utilizingtheadjuvantpropertiesofcd1ddependentnktcellsintcellmediatedimmunotherapy AT stratfordi utilizingtheadjuvantpropertiesofcd1ddependentnktcellsintcellmediatedimmunotherapy AT harrisa utilizingtheadjuvantpropertiesofcd1ddependentnktcellsintcellmediatedimmunotherapy AT cerundolov utilizingtheadjuvantpropertiesofcd1ddependentnktcellsintcellmediatedimmunotherapy |